A pharmaceutical composition for the treatment of interleukin-6 (IL-6) relateddiseases, comprising an interleukin-6 antagonist (IL-6 antagonist) andimmunosuppressants. The IL-6 antagonist is preferably an antibody to aninterleukin-6 receptor (IL-6R).